Cullinan Therapeutics, Inc. Common Stock (CGEM) is a publicly traded Healthcare sector company. As of July 28, 2026, CGEM trades at $17.26 with a market cap of $1.05B and a P/E ratio of 0.00. CGEM moved -0.52% today. Year to date, CGEM is +68.41%; over the trailing twelve months it is +113.08%. Its 52-week range spans $5.68 to $19.43. Analyst consensus is strong buy with an average price target of $33.56. Rallies surfaces CGEM's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies AI research for CGEM combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.
| Metric | Value |
|---|---|
| Price | $17.26 |
| Market Cap | $1.05B |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $19.43 |
| 52-Week Low | $5.68 |
| Volume | 47.34K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-219.88M |
| Gross Margin | 0.00% |
11 analysts cover CGEM: 0 strong buy, 11 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $33.56.